SirTlab Corporation News
1 article
growth-positive
SIRTLab Corporation Appoints Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer
SIRTLab Corporation has appointed Michael G. Kauffman as Co-Chairman of the Board of Directors and Chief Medical Officer. Dr. Kauffman has a background in the biotechnology industry and has made major contributions to the approvals of three cancer drugs. SIRTLab focuses on the manipulation of sirtuin proteins for the treatment of severe liver diseases and longevity. Their lead program is centered around sirtuin 6 (SIRT6), which has shown promising results in restoring energy homeostasis, improving metabolic profiles, and prolonging lifespan in mice. The company aims to develop agents for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. The appointment of Dr. Kauffman is seen as a significant advancement for SIRTLab as they prepare to advance their novel class of agents.
Management Changes
